Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
Profitability Metrics
Gross Margin
15.79%
Operating Margin
13.14%
Net Margin
-3.84%
Efficiency Metrics
Revenue per Expense Ratio
1.15
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
17.44%
Income Tax Rate
66,300,000.0%
EPS
-1.0800000000
Balance Sheet Analysis
Current Ratio
19.17
Cash Ratio
5.86
Working Capital
$281.60M
Debt to Equity
0.02
Debt to Assets
23.02%
Equity Ratio
1,469.9%
Cash Flow Analysis
Operating Cash Flow Ratio
5.30%
Free Cash Flow Ratio
-0.07%
CapEx to Revenue
5.37%
Dividends Paid
$76.28M
Stock Buybacks
$469.00K
Total Shareholder Returns
$76.75M
Cash Position Change
-18.88%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 49.59%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
12.96%
Net Income
1.82%
EPS
1.82%
Operating Income
-45.76%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
96,173,009,632.36%
Operating Cash Flow
-33.32%
Free Cash Flow
-101.65%
Balance Sheet Health
Assets
748.99%
Debt
4,554.97%
Book Value per Share
171.62%
Inventory
-1.53%
Shareholder Returns
Dividends per Share
49.59%
Shares Outstanding
-0.25%
Long Term Trends
3Y Revenue/Share
49.40%
5Y Revenue/Share
1,568.16%
3Y Dividend/Share
182.56%
5Y Dividend/Share
312.73%